
Alembic Pharmaceuticals Limited has secured final approval from the US FDA for Bromfenac Ophthalmic Solution, 0.07%. This nonsteroidal anti-inflammatory drug (NSAID) is indicated for managing postoperative inflammation and reducing ocular pain following cataract surgery. The approved ANDA is deemed therapeutically equivalent to Bausch & Lomb's Prolensa Ophthalmic Solution, 0.07%. With an estimated market size of $168 million for the twelve months ending March 2024 (as per IQVIA), Alembic's new approval marks a significant milestone in expanding its portfolio of ophthalmic solutions in the US market.
Like
Save
Share